Resolution of sleepiness and fatigue: A comparison of bupropion and selective serotonin reuptake inhibitors in subjects with major depressive disorder achieving remission at doses approved in the European Union

Journal of Psychopharmacology

Volumn 28, Issue 2, 2014, Pages 118-124

  Cooper, James A ^a   Tucker, Vivian L ^b   Papakostas, George I ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bupropion; fatigue; major depressive disorder; remission; sleepiness

Indexed keywords

AMFEBUTAMONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; EUROPEAN UNION; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; HYPERSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SOMNOLENCE; TREATMENT OUTCOME;

BUPROPION; FATIGUE; MAJOR DEPRESSIVE DISORDER; REMISSION; SLEEPINESS;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EUROPEAN UNION; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS;

EID: 84892915342     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113514878     Document Type: Article

References (50)

1. American Psychiatric Association (2010) Practice guideline for the treatment of patients with major depressive disorder, third edition. Available at: http://www.guideline.gov/content.aspx?id=24158 (accessed 29 September 2013).
2. Washington, DC: American Psychiatric Association ; 1994 :
3. Ascher JA, Cole JO, Colin JN, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995 ; 56: 395-401
4. Baker M, Dorzab J, Winokur G, et al. Depressive disease: Classification and clinical characteristics. Compr Psychiatry. 1971 ; 12: 354-365
5. Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiatry. 2006 ; 67: S9 - S15
6. Clayton AH, Croft H, Horrigan JP, et al. Bupropion XL compared with escitalopram: effects on sexual functioning and antidepressant efficacy in two randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006 ; 67: 736-746 (Pubitemid 43946180)
7. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained-release and sertraline treatment. Ann Clin Psychiatry. 1999 ; 11: 205-215
8. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther. 2001 ; 23: 1040-1058 (Pubitemid 32709626)
9. Connolly KR, Thase ME. Emerging drugs for major depressive disorder. Expert Opin Emerg Drugs. 2012 ; 17: 105-126
10. Croft H, Settle E, Houser T, et al. A Placebo-Controlled Comparison of the Antidepressant Efficacy and Effects on Sexual functioning of Sustained Release Bupropion and Sertraline. Clin Ther. 1999 ; 21: 643-658 (Pubitemid 29252088)
11. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: A preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003 ; 64: 1057-1064 (Pubitemid 37158251)
12. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005 ; 8: 93-105 (Pubitemid 40388818)
13. Dhillon S, Yang LP, Curran MP. Bupropion: A review of its use in the management of major depressive disorder. Drugs. 2008 ; 68: 653-689 (Pubitemid 351484811)
14. El Mansari M, Guiard BP, Chernoloz O, et al. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther. 2010 ; 16: e1 - e17
15. European Medicines Agency (2010) Press release: European Medicines Agency recommends restricting the use of modafinil. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/Press-release/2010/07/WC500094976.pdf (accessed 29 September 2013).
16. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005a ; 7: 106-113 (Pubitemid 41783226)
17. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005b ; 66: 85-93
18. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007 ; 19: 153-159 (Pubitemid 47345870)
19. Feighner JP, Gardner EA, Johnston JA, et al. Double-Blind Comparison of Bupropion and Fluoxetine in Depressed Outpatients. J Clin Psychiatry. 1991 ; 52: 329-335
20. Ferguson JM. SSRI Antidepressant medications: Adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001 ; 3: 22-27 (Pubitemid 33807486)
21. Gourion D. Antidepressants and their onset of action: A major clinical, methodological and prognostical issue. L'Encephale. 2008 ; 34: 73-81
22. Horwath E, Johnson J, Weissman MM, et al. The validity of major depression with atypical features based on a community study. J Affect Disord. 1992 ; 26: 117-125
23. International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) guidelines (ICH - 1996) Guideline for good clinical practice E6(R1). Available at: http://www.ich.org (accessed 25 November 2013).
24. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006 ; 67: 865-873 (Pubitemid 44049084)
25. Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000a ; 57: 375-380 (Pubitemid 30202328)
26. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry. 2000b ; 157: 1501-1504
27. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry. 1997 ; 58: 532-537 (Pubitemid 28100273)
28. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry. 2006 ; 51: 234-42
29. Kurian BT, Greer TL, Trivedi MH. Strategies to enhance the therapeutic efficacy of antidepressants: Targeting residual symptoms.. Expert Rev Neurother. 2009 ; 9: 975-984
30. Lam JY, Freeman MK, Cates ME. Modafinil augmentation for residual symptoms of fatigue in patients with a partial response to antidepressants. Ann Pharmacother. 2007 ; 41: 1005-1012 (Pubitemid 46917627)
31. Maurice-Tison S, Verdoux H, Gay B, et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract. 1998 ; 48: 1245-1246 (Pubitemid 28221102)
32. Minzenberg MJ, Carter CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008 ; 33: 1477-1502 (Pubitemid 351684703)
33. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999 ; 60: 221-225 (Pubitemid 29193918)
34. Ninan PT, Hassman HA, Glass SJ, et al. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. J Clin Psychiatry. 2004 ; 65: 414-420
35. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007 ; 21: 461-471 (Pubitemid 47106935)
36. Papakostas GI, Cooper JA, Richard NE. Resolution of sleepiness and fatigue: A comparison of bupropion and SSRIs in Patients achieving remission in MDD. Eur Psychiatry. 2008 ; 23: S205
37. Papakostas GI, Hallett LA, Smith J, et al. A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat. 2007 ; 3: 169-172 (Pubitemid 46779930)
38. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006 ; 60: 1350-1355 (Pubitemid 44838537)
39. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: An important outcome in depression. Psychol Med. 1995 ; 25: 1171-1180
40. Pedrelli P, Baer L, Losifescu DV, et al. Relationship between residual symptoms of depression and self-reported cognitive impairment. CNS Spectr. 2010 ; 15: 46-51
41. Posternak MA, Zimmerman M. Symptoms of atypical depression. Psychiatry Res. 2001 ; 104: 175-181 (Pubitemid 33050018)
42. Schatzberg AF. Pharmacologic treatments of major depression: Are two mechanisms really better than one?. J Clin Psychiatry. 2004 ; 65: S3 - S4
43. Stahl SM, Zhang L, Damatarca C, et al. Brain circuits determine destiny in depression: A novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry. 2003 ; 64: S6 - S17
44. Thase ME, Fava M, DeBattista C, et al. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: A 12-week, open-label, extension study. CNS Spectr. 2006 ; 11: 93-102
45. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005 ; 66: 974-981 (Pubitemid 41191788)
46. Trivedi MH, Hollander E, Nutt D, et al. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008 ; 69: 246-258 (Pubitemid 351469268)
47. Tylee A, Gastpar M, Lepine JP, et al. DEPRES II (Depression Research in European Society II): A patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol. 1999 ; 14: 139-151 (Pubitemid 29348767)
48. Weihs KL, Settle EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry. 2000 ; 61: 96-202
49. Worthington J, Fava M, Davidson K, et al. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995 ; 31: 223-226
50. Zimmerman M, McGlinchey JB, Posternak MA, et al. Remission in depressed outpatients: More than just symptom resolution?. J Psychiatr Res. 2008 ; 42: 797-801 (Pubitemid 351787737)